Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet Oncology.[1] …
Continue reading →
Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer remains …
Continue reading →
The National Comprehensive Cancer Network (NCCN)—a not-for-profit alliance of 21 cancer centers—has released guidelines for lung cancer screening. The guidelines recommend screening with helical low-dose computed tomography (LDCT) for selected patients at high risk of the disease. Lung cancer is the leading cause of cancer death among both men and women in the United States. [...]
Results from the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial provide convincing evidence that using chest x-rays to screen for lung cancer does not reduce lung cancer deaths. These results were published in the Journal of the American Medical Association. Lung cancer is the leading cause of cancer death among both men and [...]
Picking the Cancer Treatment That Works Best for You- Ask the Expert about Personalized Medicine Live Web Chat with David Sidransky, MD, Johns Hopkins Medicine, Baltimore, MD, click here for bio Dr. David Sidransky is an award-winning oncologist and a world leading authority in the field of molecular diagnostics, targeted therapies and individualized patient treatments. [...]
According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women are diagnosed with cancer during pregnancy, data regarding the effects of chemotherapy during pregnancy are limited. Determining [...]
A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals of Surgery. Clinical trials are the process through which medications ultimately become approved by the [...]
The investigational drug PF299804 (PF-299) improves progression-free survival compared with Tarceva® (erlotinib) among patients with advanced non-small cell lung cancer (NSCLC) that has progressed following treatment with chemotherapy. These results were recently presented at the 14th World Conference on Lung Cancer. Lung cancer remains the leading cause of cancer death in the United States. Non–small [...]
Although still in investigative stages, the electronic nose (eNose) may help to screen for lung cancer among individuals at a high risk of developing lung cancer. These results were recently presented the 14th annual World Conference on Lung Cancer sponsored by the International Association for the Study of Lung Cancer (IASLC). Lung cancer remains the [...]
The invasive and costly procedure of inserting an inferior vena cava filter (IVCF) does not benefit cancer patients who are being treated with the anticoagulation medication fondaparinux (Arixtra®) for blood clots. These results were recently presented at the 14th World Conference on Lung Cancer. Blood clots are the second most common cause of death among [...]
